Baidu
map

科学家发现阻止乳腺癌转移的新方法

2016-05-26 佚名 来宝网

杜克癌症研究所的科学家们乳腺癌细胞用于入侵小鼠骨髓的分子钥匙,入侵到骨髓后癌细胞就可以避免被化学疗法或激素疗法清除。通过多年在小鼠上的试验,科学家们找到了对抗这种转移的方式,不光以阻止癌细胞侵入骨髓,还可以将癌细胞冲到血液中,在血液中癌细胞就可以被药物破坏了。这些发现为那些最具毁灭性的乳腺癌提供了一些信息,这些癌细胞具有被打败后卷土重来的能力。研究人员希望这些发现,如果可以在其他动物和人类试验中重




杜克癌症研究所的科学家们乳腺癌细胞用于入侵小鼠骨髓的分子钥匙,入侵到骨髓后癌细胞就可以避免被化学疗法或激素疗法清除。

通过多年在小鼠上的试验,科学家们找到了对抗这种转移的方式,不光以阻止癌细胞侵入骨髓,还可以将癌细胞冲到血液中,在血液中癌细胞就可以被药物破坏了。
这些发现为那些最具毁灭性的乳腺癌提供了一些信息,这些癌细胞具有被打败后卷土重来的能力。研究人员希望这些发现,如果可以在其他动物和人类试验中重现,最终就可以发展成治疗乳腺癌的新疗法。

杜克癌症研究所血液恶性肿瘤与细胞疗法部副教授Dorothy A. Sipkins博士称,临床研究发现乳腺癌可以早起被发现并治疗,患者可能没有任何症状。此后,5年、10年甚至15年以后,患者就可能复发。最常见的癌症转移点是骨骼。

5月26日发表在《科学转移医学》上文章中,作者描述了雌激素受体阳性肿瘤细胞是如何在小鼠血液和组织中转移的,这些细胞会专门寻找骨髓中含有E-选择素分子的血管。有了分子钥匙,也就是细胞表面上与E-选择素键合的分子,癌细胞就可以进入骨骼中的海绵组织,通常会在此处潜伏几年。据美国临床肿瘤协会统计,激素受体阳性乳腺癌是最常见的乳腺癌,这种肿瘤细胞会利用人体的雌激素或黄体酮来生长。

本文的第一作者Sipkins称,在人体中,这些潜伏的细胞可以以后再复活,导致癌症转移复发,这种病情是无法治愈的。人类乳腺癌患者的骨髓切片显示即使在癌症早期,转移的癌细胞就可以从乳腺中转移到骨髓中。

一种对策就是找到可以抑制E-选择素的方法,这样就可以限制癌细胞迁移入骨骼并复发的能力。科学家们用一种名为GMI-1271的E-选择素抑制剂,这个抑制剂目前正在人类临床试验中。发现这个化合物可以成功阻止癌细胞进入小鼠骨髓。

因为癌细胞的微观转移到骨髓可能会在患者被确诊前就发生了,研究人员还对另一种方法进行了测试,这种方法可以将癌细胞赶出它们在骨髓里的安全屋,回到循环系统。科学家们给小鼠用普乐沙福,这是一种用于人体骨髓捐献者的药物,可以将干细胞赶入血液循环中。

Sipkins称,这个药物可以将潜伏的乳腺癌细胞从骨组织中赶到血液中。研究人员认为使癌细胞赶回血液可以给免疫系统、化疗或激素疗法新的杀死癌细胞的机会。她和同事希望能对此方法进行进一步研究。

我们希望能通过了解癌细胞如何在体内迁移和它们的生命周期,来发现使癌细胞更加脆弱更好对付。我们希望能在小鼠的研究上有更多进展,来对此有更深入的了解,然后再进行人体试验。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1802324, encodeId=9a76180232484, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Feb 26 22:54:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138083, encodeId=e2f61380834d, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:40:13 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903134, encodeId=742819031346d, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Mar 26 17:54:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122001, encodeId=be1312200102, content=好文章,百姓也能从中学到好多医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88370, encodeId=62d8883e02d, content=希望能早日用于临床,选福病人。, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/D851CE42785F5B04D82B3AC9471D6266/100, createdBy=84751732292, createdName=QQ8ac9944a, createdTime=Fri Jun 03 16:49:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590277, encodeId=7d0a15902e7ae, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat May 28 07:54:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87294, encodeId=e7688e294a1, content=希望早日应用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160515/IMG57380B859AD1F1019.jpg, createdBy=2c5c1621956, createdName=jasonuclear, createdTime=Fri May 27 01:49:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1802324, encodeId=9a76180232484, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Feb 26 22:54:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138083, encodeId=e2f61380834d, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:40:13 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903134, encodeId=742819031346d, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Mar 26 17:54:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122001, encodeId=be1312200102, content=好文章,百姓也能从中学到好多医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88370, encodeId=62d8883e02d, content=希望能早日用于临床,选福病人。, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/D851CE42785F5B04D82B3AC9471D6266/100, createdBy=84751732292, createdName=QQ8ac9944a, createdTime=Fri Jun 03 16:49:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590277, encodeId=7d0a15902e7ae, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat May 28 07:54:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87294, encodeId=e7688e294a1, content=希望早日应用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160515/IMG57380B859AD1F1019.jpg, createdBy=2c5c1621956, createdName=jasonuclear, createdTime=Fri May 27 01:49:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-09-30 1e10c84am36(暂无匿称)

    拜读,好文

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1802324, encodeId=9a76180232484, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Feb 26 22:54:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138083, encodeId=e2f61380834d, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:40:13 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903134, encodeId=742819031346d, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Mar 26 17:54:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122001, encodeId=be1312200102, content=好文章,百姓也能从中学到好多医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88370, encodeId=62d8883e02d, content=希望能早日用于临床,选福病人。, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/D851CE42785F5B04D82B3AC9471D6266/100, createdBy=84751732292, createdName=QQ8ac9944a, createdTime=Fri Jun 03 16:49:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590277, encodeId=7d0a15902e7ae, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat May 28 07:54:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87294, encodeId=e7688e294a1, content=希望早日应用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160515/IMG57380B859AD1F1019.jpg, createdBy=2c5c1621956, createdName=jasonuclear, createdTime=Fri May 27 01:49:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1802324, encodeId=9a76180232484, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Feb 26 22:54:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138083, encodeId=e2f61380834d, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:40:13 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903134, encodeId=742819031346d, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Mar 26 17:54:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122001, encodeId=be1312200102, content=好文章,百姓也能从中学到好多医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88370, encodeId=62d8883e02d, content=希望能早日用于临床,选福病人。, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/D851CE42785F5B04D82B3AC9471D6266/100, createdBy=84751732292, createdName=QQ8ac9944a, createdTime=Fri Jun 03 16:49:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590277, encodeId=7d0a15902e7ae, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat May 28 07:54:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87294, encodeId=e7688e294a1, content=希望早日应用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160515/IMG57380B859AD1F1019.jpg, createdBy=2c5c1621956, createdName=jasonuclear, createdTime=Fri May 27 01:49:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-09-11 1e10c84am36(暂无匿称)

    好文章,百姓也能从中学到好多医学知识

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1802324, encodeId=9a76180232484, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Feb 26 22:54:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138083, encodeId=e2f61380834d, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:40:13 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903134, encodeId=742819031346d, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Mar 26 17:54:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122001, encodeId=be1312200102, content=好文章,百姓也能从中学到好多医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88370, encodeId=62d8883e02d, content=希望能早日用于临床,选福病人。, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/D851CE42785F5B04D82B3AC9471D6266/100, createdBy=84751732292, createdName=QQ8ac9944a, createdTime=Fri Jun 03 16:49:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590277, encodeId=7d0a15902e7ae, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat May 28 07:54:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87294, encodeId=e7688e294a1, content=希望早日应用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160515/IMG57380B859AD1F1019.jpg, createdBy=2c5c1621956, createdName=jasonuclear, createdTime=Fri May 27 01:49:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-06-03 QQ8ac9944a

    希望能早日用于临床,选福病人。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1802324, encodeId=9a76180232484, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Feb 26 22:54:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138083, encodeId=e2f61380834d, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:40:13 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903134, encodeId=742819031346d, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Mar 26 17:54:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122001, encodeId=be1312200102, content=好文章,百姓也能从中学到好多医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88370, encodeId=62d8883e02d, content=希望能早日用于临床,选福病人。, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/D851CE42785F5B04D82B3AC9471D6266/100, createdBy=84751732292, createdName=QQ8ac9944a, createdTime=Fri Jun 03 16:49:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590277, encodeId=7d0a15902e7ae, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat May 28 07:54:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87294, encodeId=e7688e294a1, content=希望早日应用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160515/IMG57380B859AD1F1019.jpg, createdBy=2c5c1621956, createdName=jasonuclear, createdTime=Fri May 27 01:49:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1802324, encodeId=9a76180232484, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Feb 26 22:54:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138083, encodeId=e2f61380834d, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:40:13 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903134, encodeId=742819031346d, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Mar 26 17:54:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122001, encodeId=be1312200102, content=好文章,百姓也能从中学到好多医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88370, encodeId=62d8883e02d, content=希望能早日用于临床,选福病人。, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/D851CE42785F5B04D82B3AC9471D6266/100, createdBy=84751732292, createdName=QQ8ac9944a, createdTime=Fri Jun 03 16:49:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590277, encodeId=7d0a15902e7ae, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat May 28 07:54:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87294, encodeId=e7688e294a1, content=希望早日应用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160515/IMG57380B859AD1F1019.jpg, createdBy=2c5c1621956, createdName=jasonuclear, createdTime=Fri May 27 01:49:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-05-27 jasonuclear

    希望早日应用于临床

    0

相关资讯

Nat Chem Biol:揭示乳腺癌细胞招募抑制性细胞促进肿瘤发展的分子机理

并不是每一块乳腺癌肿瘤组织都遵循相同的途径来生长,有些肿瘤需要有髓源性抑制细胞(MDSCs)才能够生长,髓源性抑制细胞是一类特殊的免疫细胞,其会抑制机体抵御肿瘤的反应,然而乳腺癌细胞如何“招募”髓源性抑制细胞目前研究人员并不清楚。

重磅!卫材新型抗癌药Halaven中国乳腺癌III期临床获得成功,上半年向CFDA提交新药申请

日本药企卫材(Eisai)近日宣布,在中国开展的有关新型抗癌药Halaven(eribulin mesylate,甲磺酸艾瑞布林)的一项乳腺癌III期临床研究(Study 304)获得成功。该研究在中国的局部复发或转移性乳腺癌女性患者中开展,数据显示,与抗肿瘤药长春瑞滨(vinorelbine)治疗组相比,Havalen治疗组无进展生存期(PFS)得到统计学意义的显著改善,

教你一分钟看懂 乳腺癌病理报告单!

拿到这样一份乳腺癌病理报告,患者心里会有很多疑问。(+) (-)符号让患者一头雾水,这些指标表示什么?重点应该看哪些指标?哪些指标会影响治疗?小医生今天邀请到北京肿瘤医院的薛教授,教您一分钟看懂乳腺癌病理报告!

J Clin Oncol:他莫昔芬对乳腺癌患者生存率的影响

目的本研究的目的是评估相比不规律治疗的乳腺癌患者而言,规律服用他莫昔芬2年的乳腺癌患者的治疗效果,并对她们进行长期随访和追踪调查(> 25年)。 方法564名绝经前出现原发性乳腺癌患者被随机分配到2组,实验组患者2年内规律服用他莫昔芬(N=276),对照组不接受系统性治疗(N=288)。 通过随访收集患者的总体死亡率(CM)和乳腺癌相关死亡率(CBCM)。平均随访时长为26.3年(22.7-

Nature:新一代mTOR抑制剂有望治疗多种耐药性肿瘤

在一项新的研究中,来自美国加州大学旧金山分校和纪念斯隆-凯特琳癌症中心等机构的研究人员开发出一种潜在的抗癌药物,该药物利用一种独特的策略阻断mTOR,其中mTOR是一种有助促进多种癌症生长的分子。在动物实验中,这种药物降低对较早一代mTOR抑制剂产生耐药性的肿瘤大小。

Am J Clin Nutr:维生素C和绝经后乳腺癌风险有什么关系

维生素C摄入量和乳腺癌风险之间的关系,在实验和流行病学研究中取得了相互矛盾的结果。因此研究者进行了一项研究,探究维生素C的摄入量和乳腺癌风险之间的关系,同时将膳食维生素C的摄入量考虑在内。1995-2008年期间,该研究共纳入了57,403名绝经后妇女,在随访的581,085人年期间,共发生了2482例浸润性乳腺癌。在1993-1995年,通过食物频率问卷调查获取参与者的膳食维生素C摄入情况,并在

Baidu
map
Baidu
map
Baidu
map